Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More
Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More
This Competitive Intelligence report about Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More evaluates the landscape of the next wave of investigational antibodies in development as biosimilars of marketed antibodies in regulated and less regulated markets as of December 2019.
Cancer antibodies Avastin, Herceptin and Rituxan/MabThera and anti-TNF antibodies Remicade, Enbrel and Humira were the targets of the first wave of biosimilar antibody developments. With the approval and launch of first wave biosimilar antibodies in regulated and less regulated markets, biosimilar antibody developers and manufacturers have directed their business activity towards the next wave of possible biosimilar antibodies.
The coming wave of patent expiries and loss of market exclusivity in the US and in the European Union has spurred the development of biosimilar antibodies for ophthalmic, metabolic, anti-inflammatory and anti-autoimmune antibodies. While developers in regulated markets focus their activity on those marketed antibodies with patent expiration and loss of market protection until 2025, developers for less regulated markets are already looking beyond the year 2025.
This report evaluates the competitive situation of biosimilar antibody developments in regulated and less regulated markets including
- Lucentis
- Eylea
- Prolia/XGEVA
- Xolair
- Stelara
- Soliris
- Erbitux
- Perjeta
- Synagis
- Yervoy
- Cimzia
- (Ro)Actemra
- Simponi
- Orencia
- Tysabri
- Ilaris
- Opdivo
- Keytruda
- Tecentriq
- Cyramza
- Cosentyx
- Darzalex
- Entyvio
The report provides an overview of the year of the first approval in the US and the EU and global sales in 2018 of these marketed antibodies.
This report includes a compilation of currently active projects in research and development of further biosimilar antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.
Table of Contents
Overview Biosimilar Antibodies: First Approvals, 2018 Sales & Number of Projects
Lucentis Reference Product
Lucentis Biosimilars in Regulated Markets
Lucentis Biosimilars in Less Regulated Markets
Eylea Reference Product
Eylea Biosimilars in Regulated Markets
Eylea Biosimilars in Less Regulated Markets
Prolia/XGEVA Reference Product
Prolia/XGEVA Biosimilars in Regulated Markets
Prolia/XGEVA Biosimilars in Less Regulated Markets
Xolair Reference Product
Xolair Biosimilars in Regulated Markets
Xolair Biosimilars in Less Regulated Markets
Stelara Reference Product
Stelara Biosimilars in Regulated Markets
Stelara Biosimilars in Less Regulated Markets
Soliris Reference Product
Soiris Biosimilars in Regulated Markets
Soliris Biosimilars in Less Regulated Markets
Erbitux Reference Product
Erbitux Biosimilars in Regulated Markets
Erbitux Biosimilars in Less Regulated Markets
Perjeta Reference Product
Perjeta Biosimilars in Regulated Markets
Perjeta Reference Product
Synagis Reference Product
Synagis Biosimilars in Regulated Markets
Synagis Biosimilars in Less Regulated Markets
Yervoy Reference Product
Yervoy Biosimilars in Regulated Markets
Yervoy Biosimilars in Less Regulated Markets
Cimzia Reference Product
Cimzia Biosimilars
(Ro)Actemra Reference Product
(Ro)Actemra Biosimilars in Regulated Markets
Simponi Reference Product
Simponi Biosimilars
Orencia Reference Product
Orencia Biosimilars
Tysabri Reference Product
Tysabri Biosimilars
Ilaris Reference Product
Ilaris Biosimilars
Opdivo Reference Product
Opdivo Biosimilars in Regulated Markets
Opdivo Biosimilars in Less Regulated Markets
Keytruda Reference Product
Keytruda Biosimilars
Tecentriq Reference Product
Tecentriq Biosimilars
Cyramza Reference Product
Cyramza Biosimilars
Cosentyx Reference Product
Cosentyx Biosimilars
Darzalex Reference Product
Darzalex Biosimilars
Entyvio Reference Product
Entyvio Biosimilars